Haleh Farzanmehr, MD - 0101245916 - Academic Appointments, Publications

	Haleh Farzanmehr, MD	LICENSE # 0101245916

	haleh_farzanmehr@yahoo.com	Issue Date: 6/18/2009 Expiration Date: 2/28/2026 Status: Current Active

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Academic Appointments

Last Updated 2/3/2024

None Reported

Academic Appointments - Non-US

Last Updated 2/3/2024

None Reported

Publications

(up to ten in the last five years)

Last Updated 2/3/2024

CLINICOPATHOLOGICAL FEATURES AND MICROSATELLITE INSTABILITY (MSI) IN COLORECTAL CANCERS FROM AFRICAN AMERICANS, Int.J. Cancer: 116,914-919, 2005
Int.J. Cancer
116,914-919, 2005
Date: 01 2005

PERSISTENT CUTANEOUS HYPERPIGMENTATION AFTER TYROSINE KINASE INHIBITION WITH IMATINIB FOR GIST. Dermatol Online J. 2008; 14 (7):7 18718191
Dermatology Online J.
2008; 14 (7):7 18718191
Date: 01 2008

SUNITINIB-ASSOCIATED LYMPHOCYTIC THYROIDITIS WITHOUT CIRCULATING ANTITHYROID ANTIBODIES. Thyroid. 2008 Jul ; 18(7): 809-12 18631016
Thyroid.
2008 Jul ; 18(7): 809-12 18631016
Date: 07 2008

. SECONDARY ERYTHROCYTOSIS PRODUCED BY THE TYROSINE KINASE INHIBITORS SUNITINIB AND SORAFENIB. J Clin Oncol. 2008 Aug 20; 26(24):4047-8 1871201
Journal Clinical Oncology
2008 Aug 20; 26(24):4047-8 1871201
Date: 08 2008

DEVELOPMENT OF SQUAMOUS CELL CARCINOMA’S IN DARIER DISEASE: A NEW MODEL FOR SKIN CARCINOGENESIS?. Br J Dermatol. 2008 Sep 19; : 18808417
British Journal of Dermatology
2008 Sep 19; : 18808417
Date: 09 2008